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Research letter
Screening for coronary artery
calcium in a high-risk population:
the ROBINSCA trial
Sabine JAM Denissen1, Carlijn M van der Aalst1,
Marleen Vonder2, JanWillem C Gratama3, Henk J Adriaansen4,
Dirkjan Kuijpers5,6, Jeanine E Roeters van Lennep7,
Rozemarijn Vliegenthart2, Pim van der Harst2,8,9,
Richard L Braam10, Paul RM van Dijkman11,12,
Matthijs Oudkerk13,14 and Harry J de Koning1
Cardiovascular disease (CVD) remains the main cause
of death worldwide, accounting for 44% of all non-
communicable disease deaths, of which most are attrib-
utable to coronary heart disease (CHD).1 Coronary
artery calcification (CAC) has a strong association
with major cardiovascular events and mortality, and
has a high risk-predictive value of CHD in asymptom-
atic individuals.2,3 It has been argued that the amount
of CAC, expressed in the CAC score, can be used in
population-based screening.
The Dutch Risk Or Benefit IN Screening for
CArdiovascular disease (ROBINSCA) trial is the first
large-scale population-based randomised controlled
trial (RCT) to investigate whether CAC screening fol-
lowed by preventive treatment is effective in reducing
CHD-related morbidity and mortality in asymptomatic
individuals.4,5 The aim of this study was to investigate
the CAC prevalence and predictors in the ROBINSCA
trial, which included an asymptomatic high-risk poten-
tial target population from the general population.
The rationale and design of the ROBINSCA trial
have been described before.5 Briefly, 43,447 potentially
high-risk women (55–74 years) and men (45–74 years)
from the national population registry who completed a
baseline questionnaire to assess sociodemographic and
health characteristics and gave informed consent were
randomly allocated (1:1:1) to either the control arm,
intervention arm A (screening according to traditional
risk factors) or intervention arm B (CAC screening).
The current study focuses on the CAC screening arm
(Figure 1). The Minister of Health authorised the
ROBINSCA trial in 2013.
CAC screening was performed using computed
tomography scanning to identify CVD risk according
to the CAC score, which represents the total amount of
any CAC.6 CAC scores were categorised into low
(Agatston 0–99), high (Agatston 100–399) and very
high (Agatston 400) risk.2
The effects of baseline characteristics on CAC
score were analysed using a two-step approach regres-
sion analyses for modelling presence, both any CAC
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Figure 1. Flowchart of the ROBINSCA trial study design in which CAC scoring is performed in intervention arm B. BMI: body mass
index; CAC: coronary artery calcium; CHD: coronary heart disease; CT: computed tomography; CVD: cardiovascular disease; CVRM:
cardiovascular risk management; SCORE: systematic coronary risk evaluation.
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and CAC score of 400 or higher (multivariable back-
ward logistic regression), and extent (multivariable
backward linear regression of the log-transformed
CAC score) of CAC in women and men separately.
Variables included in the models were age, education-
al level, waist circumference cut-off (88 cm for women
and 102 cm for men), body mass index (BMI) cut-off
(30 kg/m2), family history of CHD, smoking, diabetes
mellitus, hypertension and/or hypercholesterolemia in
the past year, and baseline use of either antihyperten-
sive or lipid-lowering medication (according to self-
reported data from the baseline questionnaire). A P
value of less than 0.05 was considered statistically sig-
nificant. All analyses were performed using IBM SPSS
Statistics version 24.0.
Of the 12,950 screened participants, 48.1% were
women and 94.2% were born in The Netherlands.
The median age was 64 years in women and 62 years
in men. Regarding CVD risk factors, 20.0% were cur-
rent smokers at baseline, 3.4% reported diabetes mel-
litus, 16.4% and 15.3% reported being diagnosed with
hypertension and hypercholesterolemia, respectively, in
the year before baseline, and 44.9% reported a family
history of CHD.
CAC was absent in 39.2% of the total study popu-
lation. Overall, 48% of women had a zero CAC score
compared to 20.7% of men in the same age category
and 31.2% of all men. Furthermore, 16.8% of women
had a CAC score of 100 or higher compared to 40.0%
of men in the same age category and 30.7% of all men.
The CAC distribution in the ROBINSCA trial is com-
pared to the German Heinz Nixdorf Recall Study and
the American Multi Ethnic Study of Atherosclerosis in
the Supplementary material.
Age, high waist circumference, family history
of CHD, smoking at baseline, diabetes mellitus,
self-reported hypertension or hypercholesterolemia at
baseline and baseline use of either antihypertensive or
lipid-lowering medication were all selected as predic-
tors in the backward regression analysis of the presence
of CAC and CAC of 400 or greater, and in the linear
regression for predicting the log-transformed CAC
extent in women (Table 1). Age, educational level,
high BMI, family history of CHD, smoking at baseline,
diabetes mellitus, self-reported hypercholesterolemia at
baseline and baseline use of either antihypertensive or
lipid-lowering medication were selected as predictors in
the analyses for men (Table 1). A higher educational
level predicted a lower CAC score in men. The compo-
sition of the predictors differed moderately in the
models for women and men.
The associations of age, male sex, diabetes mellitus
and smoking with higher CAC scores are well known.7
A lower socioeconomic status, indicated by educational
level, significantly predicted a higher extent of CAC in
men. This association is possibly a result of a less
favourable lifestyle in terms of smoking, diet and phys-
ical activity.8 Diabetes mellitus was one of the strongest
predictors of CAC presence in women. This is in line
with previous research in which diabetes mellitus was
identified to have a greater impact in women compared
to men.9 Moreover, diabetes mellitus was a strong pre-
dictor for CAC extent in both sexes, suggesting that it
is the most important risk factor for CAC development
after sex and age. Regarding BMI and waist circumfer-
ence, our results confirm earlier findings that BMI is
not a strong predictor for the presence of CAC, while
waist circumference is more predictive of CAC pres-
ence.10 The predictive value of the baseline use of
either antihypertensive or lipid-lowering medication
in CAC development was also seen in previous
research. However, statins have been associated with
increased CAC scores, but not with more CVD
events. It is suggested that statins induce CAC progres-
sion and, at the same time, plaque repair.11
This study contributes to evidence on identifying the
optimal target population for screening from the gen-
eral population that will gain most healthy life-years
from screening and subsequent treatment. All inclusion
criteria for the ROBINSCA trial (smoking, waist cir-
cumference, BMI and a family history of CHD) were
statistically significant predictors of CAC. Future anal-
yses should provide evidence on whether the study pop-
ulation includes individuals who benefit most.
A main limitation is that the ROBINSCA popula-
tion is not representative of all ethnic groups as a result
of a homogeneous distribution, although ethnicity is
known to affect CAC prevalence and severity.
Another possible limitation is that study participants
tend to be generally healthier than similar individuals
not responding to the participation invitation
(healthy volunteer effect). However, the inclusion and
exclusion criteria should have minimised this effect.
Furthermore, participants using both cholesterol-
lowering and antihypertensive medication were exclud-
ed from the trial, which might have affected the
found associations of CAC with CVD medication.
Finally, baseline data were obtained using a self-
reported questionnaire, rather than diagnostic test
measures, and might entail some inaccuracies.
In conclusion, this currently largest population-
based RCT for CAC screening in asymptomatic
middle-aged Caucasian individuals showed that
30.7% of men and 16.8% of women with a CAC
score of 100 or greater urgently require preventive
treatment. To a large extent, male sex and increasing
age, followed by diabetes mellitus and smoking, influ-
ence CAC distribution. These results can therefore help
determine the best risk prediction and prevention
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strategy should screening for a high risk of developing
CVD be (cost)-effective.
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